Horizon Pharma Strikes License Deal With Amneal Pharmaceuticals


Horizon Pharma (NASDAQ:HZNP) said it has entered a settlement and license agreement with Amneal Pharmaceuticals to resolve pending patent litigation regarding Pennsaid 2%. Under the agreement, Horizon has granted Amneal the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the U.S. under Amneal’s abbreviated new drug application beginning January 10, 2029 or earlier under certain circumstances. The agreement includes a stipulation by the parties requesting dismissal without prejudice of the lawsuit filed by Horizon in the U.S.

Subscribe to get the latest news